Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 4/20 | 0.63 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.63 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.63 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.63 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.63 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.63 |
| ▸ | DRD3 | P35462 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | HPGD | P15428 | 5/20 | 0.60 |
| ▸ | GLA | P06280 | 4/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.60 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | DRD1 | P21728 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7794600 | 0.99 | ADRA1A (0.64) | ADRA1AADRA1BADRA2AADRA2BADRA2C | |
| SCHEMBL11091036 | 0.85 | ADRA1A (0.63) | ADRA1AADRA1B | |
| SCHEMBL11087216 | 0.85 | ADRA1A (0.63) | ADRA1AADRA1B | |
| SCHEMBL11080069 | 0.84 | ADRA1A (0.64) | ADRA1AADRA1B | |
| Hydrochloric Acid SCHEMBL11084847 | 0.83 | ADRA1A (0.61) | ADRA1AADRA1BKDM4EGLAGAA | |
| SCHEMBL14369110 | 0.82 | ADRA1A (0.70) | ADRA1AADRA1BADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL11085370 | 0.82 | ADRA1A (0.62) | ADRA1AADRA1BKDM4EGLAGAA | |
| SCHEMBL11082909 | 0.82 | ADRA1A (0.64) | ADRA1AADRA1B | |
| SCHEMBL11081283 | 0.81 | ADRA1A (0.66) | ADRA1AADRA1B | |
| SCHEMBL11240874 | 0.81 | ADRA1D (0.60) | ADRA1AADRA1BADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4060615-A | ANTIHYPERTENSIVE, PHOSPHODIESTERASE INHIBITOR | MEAD JOHNSON & COMPANY (US) | 1977-11-29 | — | — | US | claimed |
| US-20010031760-A1 | Method of treating a patient having precancerous lesions with quinazoline derivatives | PAMUKCU RIFAT (US) | 2001-10-18 | — | — | US | disclosed |
| US-6262059-B1 | Method of treating a patient having precancerous lesions with quinazoline derivatives | CELL PATHWAYS, INC. | 2001-07-17 | — | — | US | disclosed |
| US-4060615-A | ANTIHYPERTENSIVE, PHOSPHODIESTERASE INHIBITOR | MEAD JOHNSON & COMPANY (US) | 1977-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031760-A1 | Method of treating a patient having precancerous lesions with quinazoline derivatives | MKI67, PCNA, NQO2 | ADRA1A 3531/4885ADRA1B 3799/4885ADRA2A 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.